A method of prevention and treatment for a neurodegenerative disease with a pan- PPAR agonist, such as bezafibrate. In particular, the present invention provides that pan- PPAR agonists enhance PPAR related responses in both the central nervous system and peripheral tissues in Huntington's disease (HD) and tauopathy. Therapeutic compositions comprising one or more pan-PPAR agonist(s), and kit thereof, for preventing and treating a neurodegenerative disease or disorder are also provided.

At least one hyperlipidemic agent selected from the group consisting of a fibrate compound (e.g. fenofibrate bezafibrate or a salt thereof) and an HMG-CoA reductase inhibitor (e.g. a statin compound for example pravastatin atorvastatin or salts thereof) is as active ingredients combined with an a-glucosidase inhibitor (e.g. voglibose and acarbose) in the pharmaceutical composition of the present invention. The proportion of the ±-glucosidase inhibitor may be about 0.001 to 50 parts by weight r...

A pharmaceutical composition comprising: (i) metformin optionally in the form one of its pharmaceutically acceptable salts; (ii) a fibrate selected from fenofibrate and bezafibrate; and optionally one or more pharmaceutically acceptable excipients is suitable for use in the treatment of non-insulin-dependent diabetes.(From US6372790 B1)

Disclosed herein is a combination product or medicament comprising at leaset one-substituted pyrrole derivative of the given formula, with one or more dyslipidemic agents selected from the group of etofibrate, fenofibrate, clofibrate, gemfibrozil, bezafibrate, ciprofibrate, clinofibrate or theofibrate. Said combination product is used in the treatment of cardiovascular diseases, Alzheimer's disease, obesity, diabetes or inflammatory diseases.

The present invention relates to a pharmaceutical composition comprising as active principles (i) metformin optionally in the form of one of its pharmaceutically acceptable salts and (ii) a fibrate chosen from fenofibrat e and bezafibrate in combination with one or more pharmaceutically acceptable excipients. These compositions are particularly suitable for the treatment o f non-insulin-dependent diabetes.

At least one hyperlipidemic agent selected from the group consisting of a fibrate compound (e.g. fenofibrate bezafibrate or a salt thereof) and an HMG-CoA reductase inhibitor (e.g. a statin compound for example pravastatin atorvastatin or salts thereof) is as active ingredients combined with an alpha-glucosidase inhibitor (e.g. voglibose and acarbose) in the pharmaceutical composition of the present invention. The proportion of the alpha-glucosidase inhibitor may be about 0.001 to 50 parts by we...